Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;78(17):1847-1853.
doi: 10.1007/s40265-018-1013-4.

Duvelisib: First Global Approval

Hannah A Blair  1
Affiliations
Review

Duvelisib: First Global Approval

Hannah A Blair. Drugs. 2018 Nov.

Abstract

Duvelisib (Copiktra™) is a small-molecule inhibitor of phosphatidylinositol-3 kinase that has been developed as an oral treatment for various cancer indications. In September 2018, duvelisib received its first global approval in the USA for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib was also granted accelerated approval in the USA for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Clinical development for various haematological malignancies is ongoing worldwide, as well as preclinical development for solid tumours in the USA. This article summarizes the milestones in the development of duvelisib leading to these first approvals for CLL/SLL and FL.

PubMed Disclaimer

References

    1. Blood. 2018 Feb 22;131(8):888-898 - PubMed
    1. Leukemia. 2015 Sep;29(9):1811-22 - PubMed
    1. Blood. 2018 Feb 22;131(8):877-887 - PubMed
    1. Blood. 2014 Dec 4;124(24):3583-6 - PubMed
    1. Chem Biol. 2013 Nov 21;20(11):1364-74 - PubMed

MeSH terms

LinkOut - more resources